Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Invikafusp alfa |
Synonyms | |
Therapy Description |
STAR0602 (invikafusp alfa) is a bifunctional antibody-fusion molecule comprising an antibody that targets Vbeta6 and Vbeta10 T-cell receptors fused to IL-2, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 38019931). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Invikafusp alfa | STAR-0602|STAR 0602|STAR0602 | Invikafusp alfa is a bifunctional antibody-fusion molecule comprising an antibody that targets Vbeta6 and Vbeta10 T-cell receptors fused to IL-2, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 38019931). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05592626 | Phase Ib/II | Invikafusp alfa | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |